Provided by Tiger Fintech (Singapore) Pte. Ltd.

Insulet

263.18
+0.57000.22%
Post-market: 263.180.00000.00%19:28 EDT
Volume:564.50K
Turnover:148.22M
Market Cap:18.48B
PE:45.50
High:264.62
Open:260.92
Low:257.62
Close:262.61
Loading ...

U.S. RESEARCH ROUNDUP-3M, Citigroup, F5

Reuters
·
03 Jan

TD Cowen Reaffirms Their Buy Rating on Insulet (PODD)

TIPRANKS
·
03 Jan

Insulet Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
03 Jan

GEHC vs. PODD: Which Stock Is the Better Value Option?

Zacks
·
01 Jan

Insulet Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
31 Dec 2024

Insulet price target raised to $300 from $270 at BTIG

TIPRANKS
·
30 Dec 2024

U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent

Reuters
·
30 Dec 2024

Insulet Corp : Btig Raises Target Price to $300 From $270

THOMSON REUTERS
·
30 Dec 2024

BTIG Raises Price Target on Insulet to $300 From $270, Maintains Buy Rating

MT Newswires Live
·
30 Dec 2024

BTIG Sticks to Their Buy Rating for Insulet (PODD)

TIPRANKS
·
30 Dec 2024

Heavy Interest in Insulet’s Insulin Delivery Device

FX Empire
·
28 Dec 2024

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
27 Dec 2024

Insulet Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
25 Dec 2024

Top Research Reports for ServiceNow, AMD & Sanofi

Zacks
·
24 Dec 2024

Insulet Corp. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
24 Dec 2024

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
20 Dec 2024

Insulet Corporation (NASDAQ:PODD) Delivered A Better ROE Than Its Industry

Simply Wall St.
·
20 Dec 2024

Redburn Atlantic Raises Price Target on Insulet to $300 From $270, Keeps Buy Rating

MT Newswires Live
·
18 Dec 2024

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

Zacks
·
13 Dec 2024

Insulet Is Maintained at Overweight by JP Morgan

Dow Jones
·
13 Dec 2024